A case of unresectable hepatocellular carcinoma maintaining stable disease by using anti-vascular endothelial growth factor receptor antibody after the exacerbation of psoriasis due to small-molecule kinase inhibition-Reference-Cited by-同舟云学术

A case of unresectable hepatocellular carcinoma maintaining stable disease by using anti-vascular endothelial growth factor receptor antibody after the exacerbation of psoriasis due to small-molecule kinase inhibition

Published:2020-10-01 Issue:10 Volume:61 Page:513-519
ISSN:0451-4203
Container-title:Kanzo
language:en
Short-container-title:Acta hepatologica Japonica

Author:

Hayakawa Yuka¹,Tsuchiya Kaoru¹,Kurosaki Masayuki¹,Inada Kento¹,Kirino Sakura¹,Yamashita Koji¹,Osawa Leona¹,Sekiguchi Shuhei¹,Wang Wan¹,Okada Mao¹,Higuchi Mayu¹,Takaura Kenta¹,Maeyashiki Chiaki¹,Kaneko Shun¹,Tamaki Nobuharu¹,Yasui Yutaka¹,Nakanishi Hiroyuki¹,Itakura Jun¹,Takahashi Yuka¹,Omigawa Chika²,Minatohara Kazuya²,Izumi Namiki¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital

2. Department of Dermatology, Musashino Red Cross Hospital

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

https://www.jstage.jst.go.jp/article/kanzo/61/10/61_513/_pdf

Reference22 articles.

1. 2) Boehncke W, Schön MP. Psoriasis. Lancet 2015; 386: 983-994

2. 3) Halin C, Fahrngruber H, Meingassner JG, et al. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008; 173: 265-277

3. 4) Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Patho 2009; 90: 232-248

4. 5) He Z, Jin L, Liu ZF, et al. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br J Dermatol 2012; 167: 191-193

5. 6) Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009; 15: 1013-1015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib/ramucirumab;Reactions Weekly;2021-01